If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-16. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
== Career == Bhatia began her academic career in 1998, joining the bioengineering faculty at the University of California, San Diego (UCSD). As an assistant professor, she was awarded a five-year Packard Fellowship for Science and Engineering from the David and Lucile Packard Foundation in 1999. She was recognized with a "Teacher of the Year" award at the Jacobs School of Engineering in 2001, and was named an "Innovator under 35" by MIT Technology Review in 2003. Bhatia co-authored the first undergraduate textbook on tissue engineering, Tissue engineering (2004), written for senior-level and first-year graduate courses with Bernhard Palsson. She was a co-editor of Microdevices in Biology and Medicine (2009) and Biosensing: International Research and Development (2005). In 2005, she joined the MIT faculty in the Division of Health Sciences & Technology and the Department of Electrical Engineering and Computer Science. The Scientist named her a "Scientist to Watch" in 2006, and she became a Howard Hughes Medical Institute Investigator in 2008. Since 2013, Bhatia has expanded her affiliations within MIT and Harvard, including the Ludwig Center for Molecular Oncology (2013), the Broad Institute of MIT and Harvard (2014), the MIT Center for Neurobiological Engineering (2016), the Wyss Institute for Biologically Inspired Engineering (2018), and the Martin Trust Center for MIT Entrepreneurship (2022). Bhatia currently directs the Laboratory for Multiscale Regenerative Technologies and the Marble Center for Cancer Nanomedicine at MIT.
The war had global economic consequences: oil and gas prices surged, aviation and tourism were disrupted, and financial markets shuddered. In September 2026, daily charter rates for very large crude carriers (VLCCs) carrying up to 2 million barrels of crude from the Persian Gulf to China rose above $1.2 million, according to the Financial Times. The surge followed disruptions to oil shipping routes that forced tankers onto longer voyages and reduced the number of vessels available for hire, increasing freight costs and putting pressure on refiners' margins. International Energy Agency (IEA) head Fatih Birol described the situation as the "greatest global energy security challenge in history". The Iranian government's spokesperson, Fatemeh Mohajerani, estimated the direct and indirect cost of 40 days of war by $270 billion, or 90% of the estimated Iranian GDP in 2026. Citing Mohajerani, the Foundation for Defense of Democracies, a neoconservative think tank, estimates damages of up to $300 billion, with a middle estimation range of $144 billion. According to the Center for American Progress, as of 14 July, Americans had paid more than $68 billion in extra costs for gas and diesel since the beginning of the war, in addition to the direct war costs. According to reports, the U.S. war with Iran has cost the U.S. government approximately $40 billion as of July.
== Preservation and conditioning == The natural fibers of leather break down with the passage of time. Acidic leathers are particularly vulnerable to red rot, which causes powdering of the surface and a change in consistency. Damage from red rot is aggravated by high temperatures and relative humidities. Although it is chemically irreversible, treatments can add handling strength and prevent disintegration of red rotted leather. Exposure to long periods of low relative humidities (below 40%) can cause leather to become desiccated, irreversibly changing the fibrous structure of the leather. Chemical damage can also occur from exposure to environmental factors, including ultraviolet light, ozone, acid from sulfurous and nitrous pollutants in the air, or through a chemical action following any treatment with tallow or oil compounds. Both oxidation and chemical damage occur faster at higher temperatures. There are few methods to maintain and clean leather goods properly such as using damp cloth and avoid using a wet cloth or soaking the leather in water. Various treatments are available such as conditioners. Saddle soap is used for cleaning, conditioning, and softening leather. Leather shoes are widely conditioned with shoe polish.
Sources: en.wikipedia.org
=== Diabetes and obesity === Lacking anti-inflammatory dermal macrophages in diabetic patients results in impaired wound healing ability. Dermal macrophages are arrested at the pro-inflammatory phenotype, which increases the difficulty in the healing process due to their production of pro-inflammatory cytokines. Ulcers on foot are common in a patient with severe diabetes due to the prolonged impairment of wound healing. Pro-inflammatory (M1) macrophages are also frequently observed in obese individuals' subcutaneous tissues. This is related to the progression of diabetes with chronic adipose tissue inflammation. However, the explicit roles of dermal macrophages in obesity are still unclear.
== Death == On February 21, 1961, Jones died of lung cancer at age 67 in Minneapolis, Minnesota, predeceasing his wife, Lucille. In an obituary in the Saturday Evening Post, it was said, "Most engineers start at the bottom of a project and work up, but Fred takes a flying leap to the top of the mountain and then backs down, cutting steps for himself and the rest of us as he goes." Jones continued filing for patents almost up until his death, receiving his last patent in February 1960.
The production was held at the Eugene O'Neill Theatre in New York City to raise money for the American Foundation for Equal Rights. Freeman had a lead role in the 2012 drama The Magic of Belle Isle, as an alcoholic novelist trying to write again. The film fared poorly with critics, gaining only a 29% approval rating on Rotten Tomatoes. Lastly in 2012, Freeman reprised his role as Lucius Fox for the third time in The Dark Knight Rises. A number of box office hits were released in 2013. Freeman appeared in the action-thriller Olympus Has Fallen, the first installment in what would become the Has Fallen film series; he portrays Speaker of the House Allan Trumbull. The San Francisco Chronicle critic gave Olympus Has Fallen 3 out of 4 stars and opined that Freeman gave an amicable supporting performance. He then starred in the science fiction drama Oblivion, with co-star Tom Cruise, as veteran soldier Malcolm Beech, and appeared in the thriller Now You See Me, as an ex-magician. Lastly, he played a retiree in Last Vegas, with co-stars Michael Douglas, Robert De Niro, Kevin Kline, and Mary Steenburgen. Filmed in Las Vegas and Atlanta, Last Vegas was praised for its cast's chemistry, and one critic thought Freeman brought the most amusement. In 2014, Freeman voiced the character Vitruvius in The Lego Movie, a commercially successful 3D animation. He starred in Transcendence, a science fiction thriller directed by Wally Pfister in his directorial debut, in which Freeman plays scientist Joseph Tagger. Critic reviews of the film were generally mixed, according to Metacritic.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.